相关实验视频
Updated: May 8, 2025

03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
5.0K
在2型糖尿病的年轻人中使用持续葡萄糖监测:试点随机研究
Tejal Patel1, Nathan Grant L Sala2, Natalie A Macheret2
1Division of Diabetes and Endocrinology, Children's National Hospital, Washington, District of Columbia, USA.
Diabetes technology & therapeutics
|March 18, 2025
概括
持续的葡萄糖监测 (CGM) 是可行的和可接受的青年发病的2型糖尿病 (Y-T2D) 在不经常的监测. 设备不情愿和皮肤问题是障碍,需要进一步研究Y-T2D糖尿病管理.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 儿童糖尿病管理管理
背景情况:
- 持续血糖监测 (CGM) 改善了胰岛素治疗个体的糖尿病自我管理.
- 有限的数据存在于CGM可行性,可接受性和结果在青年发病的2型糖尿病 (Y-T2D) 使用不经常的血糖自我监测 (SMBG).
研究的目的:
- 为了评估Y-T2D中CGM的可行性和可接受性,在不常见的SMBG疗法中.
- 评估血糖控制的变化,糖尿病困扰以及CGM相关的好处/负担.
主要方法:
- 一个为期12周的随机试验试验,将CGM与Y-T2D中的SMBG (控制) 进行比较.
- 包括对照组 (控制-CGM) 的可选4周的CGM延期.
- 可行性 (招聘,参与,保留) 和可接受性 (佩戴时间) 是主要结果.
主要成果:
- 招募率为54%;不愿佩戴设备是主要障碍.
- 可接受性 (≥60%的佩戴时间) 达到56% (CGM) 和83% (Control-CGM).
- 穿戴时间在3个月内显著下降;皮肤粘附问题很常见 (75%).
结论:
- 在不常见的SMBG上,对50%以上的Y-T2D来说,CGM是可行的和可以接受的.
- 障碍包括设备不情愿和社会耻辱;皮肤粘附问题需要缓解.
- 需要进一步的研究来优化CGM在这个人群中的使用.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Diabetes: Symptoms, Diagnosis, and Complications
470
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
470
Diabetes: Management and Pharmacotherapy
203
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
203
Insulin: Dosing Regimen and Adverse Effects
121
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
121
Hypoglycemia and Glucagon
132
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
132

